Clinically-optimized for rapid implementation and
Thanks to larger, more comprehensive NGS assays, there are more opportunities than ever to improve care and outcomes for cancer patients. The newest assays provide comprehensive coverage of variants and immunotherapy biomarkers (including tumor mutational burden and microsatellite instability) and enable the tracking of mutational signatures over time. Now that these assays are commercially available for the first time, laboratories have the option of running them in-house, which can positively impact quality and crucial turnaround time.
In this educational webinar, we explore how your laboratory can rapidly validate, implement, and report using the pan cancer profiling assay.
By attending this webinar, you will: